drugset / Trial / NCT02612922

Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

NCT02612922

Phase 3 Completed 325 enrolled Romark Laboratories L.C.
RandomizedParallel-groupTriple-blindTreatment

Summary

Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of acute uncomplicated influenza.

Timeline

Start
2015-12
Primary completion
2016-09-04
Completion
2016-09-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nitazoxanide Other / unclassified 600 mg Oral

Indications